ReviewThe Analyst2010
Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer.
Review in The Analyst, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 150 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
150 citing papers in PubMed.
- Next-Generation Bionic Sensors for Small Molecule Detection: Integrating Synthetic Biology, Nanomaterials, and Artificial Intelligence.Micromachines · 2026Review
- A Sensitive Multichannel Fluorescent Polymer Sensor Array for the Detection of Protein Fluctuations in Serum.Sensors (Basel, Switzerland) · 2026Article
- Disposable electrochemical panel immunosensing systems for the simultaneous detection of potential biomarkers of ovarian cancer.Mikrochimica acta · 2026Article
- Revolutionizing cancer treatment: The multifaceted role of graphene oxide in modern oncology.Bioengineering & translational medicine · 2026Review
- Review: Detection of Cancer Biomarkers from a Clinical Perspective.International journal of molecular sciences · 2025Review
- Continuous Optical Biosensing of IL-8 Cancer Biomarker Using a Multimodal Platform.Bioengineering (Basel, Switzerland) · 2025Article
- Electrochemiluminescence immunoassay using ionic-liquid submicron particles for prostate-specific antigen determination.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2025Article
- Multiplexed CRISPR Assay for Amplification-Free Detection of miRNAs.Biosensors · 2025Article
- Preparation and application of multiple particle binding-liposomes for electrochemiluminescent signal amplification in bioassays.Analytical and bioanalytical chemistry · 2024Article
- Graphene-based hybrid composites for cancer diagnostic and therapy.Journal of translational medicine · 2024Review
- Review
- Suppression of MCP-1, IFN-γ and IL-6 production of HNSCCFrontiers in immunology · 2024Article
- Design and Analysis of a Low-Voltage VCO: Reliability and Variability Performance.Micromachines · 2023Article
- Optofluidic Flow Cytometer with In-Plane Spherical Mirror for Signal Enhancement.Sensors (Basel, Switzerland) · 2023Article
- Label-Free SERS and MD Analysis of Biomarkers for Rapid Point-of-Care Sensors Detecting Head and Neck Cancer and Infections.Sensors (Basel, Switzerland) · 2023Article
- Polyethylene Glycol-Mediated Directional Conjugation of Biological Molecules for Enhanced Immunoassays at the Point-of-Care.Polymers · 2023Article
- Biosensors with Boronic Acid-Based Materials as the Recognition Elements and Signal Labels.Biosensors · 2023Review
- Research Progress on Nanomaterials for Tissue Engineering in Oral Diseases.Journal of functional biomaterials · 2023Review
- Development of a one-shot dual aptamer-based fluorescence nanosensor for rapid, sensitive, and label-free detection of periostin.Scientific reports · 2023Article
- Electrochemical and Photoelectrochemical Immunosensors for the Detection of Ovarian Cancer Biomarkers.Sensors (Basel, Switzerland) · 2023Review
90 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This critical review evaluates progress toward viable point-of-care protein biomarker measurements for cancer detection and diagnostics. The ability to measure panels of specific, selective cancer biomarker proteins in physicians' surgeries and clinics has the potential to revolutionize cancer detection, monitoring, and therapy. The dream envisions reliable, cheap, automated, technically undemanding devices that can analyze a patient's serum or saliva in a clinical setting, allowing on-the-spot diagnosis. Existing commercial products for protein assays are reliable in laboratory settings, but have limitations for point-of-care applications. A number of ultrasensitive immunosensors and some arrays have been developed, many based on nanotechnology. Multilabel detection coupled with high capture molecule density in immunosensors and arrays seems to be capable of detecting a wide range of protein concentrations with sensitivity ranging into the sub pg mL(-1) level. Multilabel arrays can be designed to detect both high and ultralow abundance proteins in the same sample. However, only a few of the newer ultrasensitive methods have been evaluated with real patient samples, which is key to establishing clinical sensitivity and selectivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.